An Open-label Non-randomized, Phase 1 Study to Evaluate the Effect of (a) Itraconazole or Rifampin on the Pharmacokinetics of a Single Intravenous Dose of Copanlisib and (b) Copanlisib on Cardiovascular Safety in Subjects With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Trial Profile

An Open-label Non-randomized, Phase 1 Study to Evaluate the Effect of (a) Itraconazole or Rifampin on the Pharmacokinetics of a Single Intravenous Dose of Copanlisib and (b) Copanlisib on Cardiovascular Safety in Subjects With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Copanlisib (Primary) ; Itraconazole
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 23 Jun 2017 Planned number of patients changed from 58 to 46.
    • 28 Apr 2017 Planned primary completion date changed from 23 Mar 2018 to 28 Jun 2018.
    • 24 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top